INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm
INmune Bio, Inc. (NASDAQ: INMB) was featured on Fox Business News, with CEO Dr. Raymond Tesi discussing the company's planned phase two human trials for a potential COVID-19 treatment using an anti-inflammatory drug. The segment highlighted the company's focus on leveraging the patient’s innate immune system and addressing lower drug costs. INmune Bio is developing several treatments through its DN-TNF and Natural Killer Cell Priming platforms, targeting diseases such as cancer, Alzheimer's, and COVID-19 complications.
- Featured on Fox Business News, enhancing public visibility.
- Plans for phase two human trials of a COVID-19 treatment.
- Focus on reducing drug costs while developing innovative therapies.
- Clinical trials are still in early stages, with uncertain outcomes.
- No assurance of success or regulatory approvals for new treatments.
LA JOLLA, Calif, July 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease was featured on a Fox Business News segment.
Fox Business News reports: “INmune Bio CEO, President and acting CMO Dr. Raymond Tesi, M.D. talks about INmune Bio's proposed phase two human trials of possible treatment of coronavirus patients using an anti-inflammatory drug and addresses the effort for lower drug costs.”
To watch the full interview, please visit the link below: https://video.foxbusiness.com/v/6174850319001/?playlist_id=937116503001#sp=show-clips
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate™, Quellor™ and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
DMoss@INmuneBio.com
Investor Contact:
James Carbonara (646) 755-7412
James@haydenir.com
FAQ
What treatments is INmune Bio developing for COVID-19?
When was INmune Bio featured on Fox Business News?
What is the stock symbol for INmune Bio?
Who is the CEO of INmune Bio?
What other diseases is INmune Bio targeting with its treatments?
